Vitamin D as a Principal Factor in Mediating Rheumatoid Arthritis-Derived Immune Response
Rheumatoid arthritis (RA) is a systemic multifactorial autoimmune disorder. The interactions between diverse environmental and genetic factors lead to the onset of this complex autoimmune disorder. Serum levels of vitamin D (VD) are involved in the regulation of various immune responses. Vitamin D is a key signaling molecule in the human body that maintains calcium as well as phosphate homeostasis. It also regulates the functions of the immune system and, thus, can play a substantial role in the etiology of various autoimmune disorders, including RA. Low serum VD levels have been found to be associated with a higher risk of RA, although this finding has not been replicated consistently. The molecular mechanisms by which VD influences autoimmunity need to be further explored to understand how variation in plasma VD levels could affect the pathogenesis of RA. This mini-review focuses on the influence of VD and its serum levels on RA susceptibility, RA-associated complexities, treatment, and transcriptome products of key proinflammatory cytokines, along with other cytokines that are key regulators of inflammation in rheumatoid joints.
1. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune multifactorial complex disease . The key characteristic of this complex autoimmune disorder is the inflammation of the small joints [2–4]. Rheumatoid arthritis is associated with significant morbidity and mortality. The worldwide prevalence of RA is one percent . The disease is usually more common among females than males [6, 7]. Mortality data from the United Nations Population Prospects database from 1987-2011 and World Health Organization mortality database for 31 countries show that RA accounted for almost 18 percent of all deaths caused by different forms of arthritis and other musculoskeletal disorders .
The interface between diverse environmental and genetic elements leads to the onset of RA . The initial stages of RA are usually not evident clinically. One of the disease hallmarks of RA is the production of rheumatoid factor (RF) triggered by the autoimmunity. The imbalance of different immunological mediators leads to cellular damage, which in the case of RA manifests in bone and joint damage . Cytokines are an imperative regulatory element in the pathogenesis of RA. Generally, the cytokines involved in RA can be grouped into two main categories: proinflammatory and anti-inflammatory cytokines.
Tumor necrosis factor alpha (TNFα), interleukin1 (IL-1), interleukin6 (IL-6), and interleukin17 (IL-17) are key proinflammatory cytokines that play vital regulatory roles in the chronic inflammation of joints and associated cartilage and in bone deformation. TNFα is an inflammatory mediator that is arthritogenic even in its membrane-bound form . IL-1 is a central cytokine in both RA and RA-mediated destruction of cartilage. IL-6 contributes to the production of autoantibodies. IL-6 also regulates the activation and differentiation of various immune cells. These cytokines have been targeted for gaining therapeutic insights into RA . Proinflammatory cytokines have a significant role in the disease occurrence and severity of RA. Multiple genetic studies focusing on key proinflammatory cytokine genes have investigated the role of common genetic variation in relation to RA risk, disease severity index, and drug response. Polymorphisms in the regulatory regions of these cytokine genes can significantly affect the binding of various transcription factors that can influence the risk of RA [13–17]. Since the focus of this short review is on the effect of VD on proinflammatory cytokines, anti-inflammatory cytokines are not discussed here.
2. Vitamin D (1,25-Dihydroxyvitamin D)
Vitamin D (VD) is a secosteroid hormone that is produced mainly by skin under the exposure of β-radiations and UV light . Kidney and liver are major players for VD metabolism [19, 20]. It can also be supplemented through diet where gastrointestinal absorption takes it to blood circulation . VD is considered as one of the essential nutrients in the human body. Its most significant role is to maintain calcium and phosphate homeostasis. Optimal serum VD level is 30 ng/ml [22, 23]. Different forms of VD have different activity levels . Once it is generated in the body through sunlight or after body received it from food, VD is chemically converted to its active form (Figure 1). Two different enzymes generate the active form of VD. First, 25-hydroxylase, a liver enzyme, converts recently produced inactive VD to 25-hydroxyvitamin D [25(OH)D] that subsequently is activated by a kidney enzyme, 1α-hydroxylase, to form 1,25-dihydroxyvitamin D [1,25(OH)2D3] . Activated VD is responsible for maintaining calcium and phosphate homeostasis by increasing intestinal phosphate and calcium absorption. VD plays an essential role in several physiological processes, including bone formation, immunity, cellular growth, and cellular differentiation . Serum VD level variation has been implicated in various diseases, including cancer, metabolic syndrome, immune system disorders, frailty, cardiovascular disorders, and neurological disorders [27–31]. A microarray analysis has estimated that VD regulates 5% of the human genome either directly or indirectly and regulates the physiological behavior of more than 36 different cell types . Many small scale genetic and genome-wide association studies (GWAS) have implicated multiple genetic loci (GC, DHCR7, CYP2R1, CYP24A1, SEC23A, AMDHD1, A2BP1, GPR114, DAB1, MLL3, FOXA2, and HMCN1) that are involved in the synthesis, transportation, metabolism, and degradation of VD .
Vitamin D receptor (VDR) is a member of the nuclear hormone receptors’ family . VD acts as a ligand for VDR. The lipophilic 1,25(OH)2D3 can easily pass through cellular membranes and binds to its receptors without the involvement of any additional signal transduction steps, as is the case of the ligand molecules that bind to transmembrane receptors . Since VDR is ubiquitously expressed, a wide range of different cell types are responsive to VD . VDR is expressed in chondrocytes and synoviocytes present in inflamed joints of RA subjects. Genetic variation in the VDR gene has been linked to RA risk [37–40].
3. VD and Immunity
The discovery of the existence of VDR on peripheral blood mononuclear cells (PBMCs) and its role in the pathogenesis of RA laid down the foundation about the potentially important role of VD as an important immunity regulator [41–43]. VD plays a vital part in the regulation of various immunity mediated responses . It has a significant role in controlling innate and adaptive immunity but in an antagonistic manner . VD controls the innate and adaptive immune systems mainly through toll-like receptors (TLRs) and differentiation of T-cells, predominantly Th17 cells, and these Th17 cells have a crucial role in RA pathology . VD modulates the regulation and differentiation of immune cells. It controls the production and secretion of autoantibody in B-cells . It suppresses the proliferation and differentiation of B-cells by inducing apoptosis in activated B-cells . VD obstructs the T-cells proliferation and inhibits the synthesis of IL2, INF-γ, and TNFα cytokines .
4. VD and Autoimmunity
In an autoimmune response, VD is involved in maintaining an optimum balance between Th1 and Th2 to suppress the autoimmune response mediated by T cells, by regulating CD4+T cells production and activity . It also halts antigen representation . To overcome the effects of autoreactive T cells, VD increases the regulatory T cells activity . Estrogen in RA synovial tissue boosts the immune response and VD is found to downregulate the estrogen synthetase activity, hence controlling the autoimmune response . VD has an immunosuppressive effect and the physiologic concentration of VD has been shown to provide protection against autoimmune diseases [53, 54]. Changes in serum availability of VD can affect various cells and their normal signaling cascades. This can lead to disturbances in homeostasis at the molecular level, leading to onset and pathogenesis of various disorders, especially those related to calcium and bone metabolism and immune system dysfunction. Deficiency of VD has been linked to many autoimmune disorders, including insulin-dependent diabetes mellitus, systemic lupus erythematosus (SLE), and RA [55–57].
5. Vitamin D and Tumor Necrosis Factor-Alpha (TNF)
Inflammation in RA occurs due to the abundant presence of inflammation-promoting cytokines . TNFα is implicated in systemic inflammation. This is mainly synthesized by activated macrophages. Numerous other cell types can also produce TNFα, including fibroblast, monocytes, natural killer cells, and mast cells . Most of these TNFα producing cells have VDR [60, 61]. TNFα is encoded by the TNFA gene that is present on chromosome 6p21.3. The gene is ~3 kb and comprises 4 exons . TNFα promotes inflammatory signaling and performs a key role in the onset and pathogenesis of RA. The level of TNFα has been shown to be higher in RA patients than controls, as TNFα is involved in inflammation followed by joint destruction . However, the role of TNFA genetic variations in RA has not been established yet .
Studies intending to explore the effect of VD treatment on TNFα production have shown an inverse correlation between these two. This correlation has been investigated by quantification of mRNA or level of protein production and protein release in numerous studies. In PBMCs, TNFA transcriptome, as well as proteome, was reported to be inversely correlated with VD stimulation . A VDR binding sequence has been found in the promoter of TNFA. VD levels can affect the binding of VDR to its target sequences in the upstream regulatory regions of the TNFA gene, which in turn can regulate the transcription of TNFA mRNA. VD levels, however, are not linked with TNFA mRNA stability. VD, therefore, regulates TNFα at transcriptional level . A study conducted on a mouse model concluded that VD acts as a shield against RA because this promotes the apoptosis of fibroblast-like synoviocytes, which are key factors for cartilage destruction in RA . Another study conducted on healthy women showed an inverse correlation between VD and TNFα concentration and suggested the preventive role of VD against inflammatory conditions .
6. Vitamin D and Interleukin-1 (IL-1)
IL-1 family is a group of 11 different cytokines . Interleukin 1 alpha (IL-1α) and interleukin 1 beta (IL-1β) are the most studied members of this immunoregulatory molecule family. These cytokines are encoded by IL1A and IL1B genes that are located on 2q14. These two cytokines have a common antagonist called IL-1 receptor antagonist (IL-1Ra). The receptor for IL-1α and IL-1β is IL-1 receptor I (IL-1RI). IL-1Ra also binds to IL-1RI but it cannot induct any intracellular signaling and thus it acts to regulate the action of IL-1α and IL-1β . IL-1β is produced by endothelial cells, monocytes, macrophages, activated T cells, and B cells . It is expressed in mononuclear blood cells and synovial membrane . It is involved in proteoglycan degradation and inhibits the synthesis of proteoglycan . IL-1β has a key role in articular damage in RA and it also elicits the production of other cytokines, especially IL-6, in RA . Studies of RA in animal models have shown the involvement of IL-1α and IL-1β in joint damage and cartilage degradation [75, 76].
IL-1β is found in infected cells and VD elevates IL-1β levels in macrophages during infection through direct transcription mechanism . Similarly, another study showed that VD induced IL-1β production in lipopolysaccharide-treated human monocytes-derived macrophages and it also increased the production and phosphorylation of IL-1β transcriptional regulatory factor (C/EBPβ-CCAAT enhancer binding protein β) . Another study conducted to find out the effect of VD on levels of proinflammatory cytokines found that VD significantly downregulated the levels of IL-1β . VD has been reported to be inversely associated with IL-1α and IL-1β levels [80, 81], although a few earlier studies reported a positive correlation of VD and IL-1α and IL-1β [82–84]. Similar to IL-6 production, the levels and kind of influence VD has on IL-1 transcriptome depends on several additional factors. In human monocytic cell lines, the presence or absence of any connection between VD levels and IL-1 expression depends on the presence/absence and the nature of costimulus being present .
7. Vitamin D and Interleukin-6 (IL-6)
IL-6 is a monomeric glycoprotein of 26 kDa that is encoded by an interleukin-6 gene (IL6) located on 7p21. The glycoprotein is arranged into four long helical chains [86, 87]. IL-6 is a pleiotropic cytokine that is released by a range of different immune cells, including epithelial cells, fibroblasts, monocytes, and T cells . The IL-6 receptor consists of two different polypeptide chains: gp130 and IL-6 receptor (IL-6R) while IL-6R specifically binds to gp130 and it serves to mediate intracellular signaling that can be either via JAK (Janus kinase)/STAT(signal transducer and activator of transcription) pathway or via mitogen-activated protein (MAP) kinase pathway [89, 90]. The STAT/JAK intracellular signaling pathway is known to play a vital role in immune-related responses that are mediated by IL-6 . IL-6 is a primary mediator of inflammation. The levels of this cytokine are considerably elevated in the serum of RA patients [92–94]. IL-6 has been known to contribute towards the production of autoantibodies and it also acts as a regulator of TH-cells differentiation . The signaling pathway triggered by IL-6 ultimately leads to joint inflammation and bone erosion in RA . IL-6 is also involved in the initiation of the acute-phase response, the proliferation of synovial fibroblasts, and the stimulation of the precursor cells of hematopoietic lineage .
Serum levels of VD have been reported to be inversely related to serum IL-6 levels . VD has been implicated as a downregulator of IL-6 mRNA levels in prostate cells. VD inhibits p38 molecule by the induction of MAPK phosphatase-1 (MKP1). This leads to the dephosphorylation of p38 by MKP1 and thus the activated p38 levels are reduced. p38 inhibition, in turn, is responsible for the reduction of IL-6 transcripts in the target cells . IL-6 expression regulation has also been correlated with the differentiation of immune cells. The expression of IL-6 has been, therefore, linked with the degree of maturation of the immune cell, cytokine, and other signaling molecules . Th17 cells are considered a crucial component of autoimmune-mediated response and 1,25(OH)2D3 has shown to stop the IL-6 expression, which in turn stimulate the production of Th17 cells [100, 101]. Exposure of VD reduces IL-6 levels in TNF- α stimulated synovial stroma cells (SSCs) from RA patients .
8. Vitamin D and Interleukin-17 (IL-17)
IL-17 is an inflammatory cytokine which is produced mainly by Th17 and other innate immune cells that have a crucial role in immune response and tissue impairment in RA . It is mostly expressed in synovial fluid and synovium of RA patients . Due to the immunomodulatory effect of VD on Th17 cells, it was found that active form of VD decreases the production of Th17 from CD4+T cells in humans and also it cuts down the expression of IL-17 in CD4+ T cells . A recent study provides support to this observation where deficiency of VD in RA patients was found to affect Th17 cells function and, hence, IL-17 production, indicating that sufficient levels of VD may guard RA patients against IL-17 mediated immune response . Some animal model studies have also reported similar findings where VD was associated with reduced production of IL-17 [107, 108]. T cells, especially Th17, are one of the main target sites for VD. VD action on T-cells halts the T-helper cells cytokines and alters the cytokine expression pattern of antigen presenting cells [109–112].
9. Vitamin D and Other Cytokines
Being an autocrine growth factor, IL-2 plays a significant role in optimum immune system functioning by acting as an activator, growth factor, and key component for T-cells differentiation [113, 114]. In the adaptive immune system, multiple T lymphocytes are favorite action sites for VD. VD is found to be an inhibitory factor for Th1 cells and subsequently reduced the production of INFγ and IL-2, which are important Th1 cytokines [115, 116]. In an in vitro study, it was found that VD regulated the Th2 production and Th2 cells were the main source of IL-2 and IL-10 production. Th2 cells are also involved in Th1 cells function inhibition . A study conducted on human T-cell line confirmed that VD suppressed the IL-2 gene expression and reduced the IL-2 production by blocking the positive regulatory elements of transcriptional factor (NFAT) within the promoter region of the IL-2 gene . In most of the cases, VD is found to downregulate the production of different cytokines, but, in case of IL-4 and IL-10, VD has an opposite effect where it upregulates the synthesis of IL-4  and IL-10 . An in vitro study showed that treatment of 1,25(OH)2D3 on CD4+Mel14+ T cells enhanced the synthesis of Th2 lymphocytes and ultimately increased the production of IL-4, IL-5, and IL-10 . IL-12 determines the fate of T cells and its levels are found to be higher in RA patients . In human PBMCs, VD was found to have an inhibitory effect on the production of IL-2 and IL-12 . VD also blocks the differentiation of a dendritic cell and thus inhibits the IL-12 production. The complex of 1,25(OH)2D3, VDR, and NFκB hinder with NFκB-derived transcription of IL-12 . VD also downregulates the production of IL-12 and IL-23 by elevating the production of IL-10 [125, 126].
10. Connection between VD and RA
Vitamin D has been shown to act as a key player in the onset and pathogenesis of RA. In murine RA, the hormonally activated form of VD (1,25-Dihydroxvitamin D3 [1,25(OH)2D3]) has been implicated in preventing the onset and RA pathogenesis . In vitro studies in different cell lines that mimic RA like pathology have revealed that VD promotes anti-inflammatory response . An In vivo study on a transgenic mouse model of RA showed that deletion of VDR was associated with inflammation followed by bone loss .
The prevalence of RA has been found to decrease in individuals with high intake of VD, including both dietary and supplemental forms of VD . Epidemiological data have revealed that a significant number of RA patients (30-63%) have decreased VD levels . VD intake is inversely associated with RA activity . Distribution of serum VD levels has been examined in a number of RA case-control studies. A vast majority of these studies have found significantly different VD levels between cases and controls and these results are summarized in Table 1. Below we summarize the outcomes of significant studies.
A study conducted on RA patients that were not taking any VD supplements found a severe deficiency of VD . A recent meta-analysis which combined data from fifteen different studies on a total of 1,143 RA patients and 963 controls reported the same inverse correlation between serum VD levels and disease severity . A similar association between disease activity score (DAS28) and serum VD levels was found . A cross-sectional study measured serum VD levels and reported VD insufficiency in a group of rheumatic patients . Another study conducted on Caucasian women also reported serum VD insufficiency in RA patients as compared to controls . A few other studies also reported a similar inverse association between VD levels and disease severity [137–141]. A recent meta-analysis combined results from different reports on 2,148 cases and 1,991 healthy controls, reported lower serum VD levels in RA patients as compared to healthy controls, and further reported an inverse correlation between serum VD levels and disease severity score . Wang et al.  studied the effect of serum VD levels on 154 RA patients and reported an inverse relationship between VD levels and disease activity and anti-CCP level. A European League Against Rheumatism (EULAR) that supported a study on 625 RA patients and 276 healthy controls from 13 different European countries also reported hypovitaminosis in RA patients and inversely correlated serum VD levels with RA-associated complexities . A study on a much larger sample size of 894 RA and 861 healthy controls reported an inverse correlation between serum VD levels and RA disease activity . Another study on 93 RA patients and 31 healthy controls from an Iranian population also reported the inverse association between serum VD levels and RA severity and suggested VD supplementation for RA treatment along with other regular medications . A study conducted on the Turkish population reported an inverse relationship between serum VD levels and RA susceptibility but did not find any association between serum VD levels and disease activity . Similar results have been published by research published on Iranian population .
Severe deficiency of VD has been reported in early inflammatory arthritis . A study conducted on 4,793 Japanese RA patients reported a severe deficiency of VD in RA patients and indicated an inverse association between levels of VD and RA related clinical symptoms . Similarly, another study conducted on European RA patients reported the same results and linked VD levels inversely with RA-associated clinical symptoms, but it did not demonstrate any correlation between serum VD levels and disease severity score . Studies conducted on the Italian population also reported VD deficiency in RA patients [152, 153]. In line with these results, data from North Italy rheumatology outpatients’ clinic demonstrated 87% prevalence of VD deficiency in patients suffering from autoimmune rheumatic diseases . Parallel to these results, almost 90% of hypovitaminosis D was reported in RA patients from the UK and Swiss outpatients clinics [155, 156]. Comorbidities in Rheumatoid Arthritis (COMORA) cohort comprising 1,431 patients from 15 different countries also found low serum VD levels with RA incidence and comorbidities . A study conducted on Saudi Arabian RA patients reported VD as a good predictor of disease activity .
In RA treatment, combination therapy of denosumab and VD increases bilateral total hips bone mineral density (H-BMD) . Another study suggested the role of VD in maintaining endothelial homeostasis in RA patients based on VD levels and CD34+ cell count in RA patients . Two more studies suggested the potential immunomodulatory role of VD that can have a promising effect in RA patients [161, 162]. VD also affects other disease parameters, including Th17 cell count and incidence of anti-CCP antibodies . Despite the immunomodulatory properties of VD, the beneficial role of VD supplementation as a component of RA treatment has produced inconsistent results [164–166].
11. VD and RA Related Complexities
A recent study in Northwest China found that RA patients with depression have much lower serum VD levels (mean= 15.24 ± 8.78 ng/mL) as compared to RA patients without depression (mean= 24.68 ± 10.98 ng/mL) and associated hypovitaminosis with depression, anxiety, and disease activity in RA patients . Another study also associated low serum VD levels with increased neuropathic pain in RA patients . Furthermore, low serum VD levels are inversely associated with ROS (reactive oxygen species) levels in RA patients . A recent data indicate that low serum VD levels in RA patients may lead to secondary osteoporosis .
The human body can synthesize VD under the exposure of β-radiations and UV light or can absorb it through food. Kidney and liver metabolize the absorbed VD. VD maintains the calcium and phosphate homeostasis in the body. VD can regulate innate and adaptive immunity mainly through B and T-cell production and differentiation. It inhibits the synthesis of IL2, INF-γ, and TNFα. Immunomodulatory properties of VD have made it an important factor in multiple autoimmune conditions. VD serum levels are inversely associated with RA susceptibility, disease activity, and related pathological complexities. VD is a significant regulator of various genes involved in the immune system and plays an important role in various immune-related responses, including the expression of proinflammatory cytokines. VD, through suppression of cytokines levels, can prevent the onset and pathogenesis of RA. Therefore, VD deficiency, coupled with genetic and environmental factors, may lead to the onset of RA. Additional studies are needed to explore the precise molecular pathways and mechanisms by which VD levels mediate RA-derived immune response. Research on the potential role of VD supplementation in RA treatment has produced inconsistent results; additional large-scale pharmacological research is required to find out the effect of VD augmentation during the treatment of RA.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
H. Zhu, F. Y. Deng, X. B. Mo, Y. H. Qiu, and S. F. Lei, “Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update,” Pharmacogenomics, vol. 15, pp. 551–566, 2014.View at: Google Scholar
V. Joshi, “Arthritis in the elderly,” Journal of the Indian Medical Association, vol. 101, pp. 408–412, 2003.View at: Google Scholar
A. A. Kiadaliri, D. T. Felson, T. Neogi, and M. Englund, “Brief report: rheumatoid arthritis as the underlying cause of death in thirty-one countries, 1987–2011: trend analysis of world health organization mortality database,” Arthritis & Rheumatology, vol. 69, no. 8, pp. 1560–1565, 2017.View at: Publisher Site | Google Scholar
B. Mulcahy, W.-L. Frank, F. M. Michael et al., “Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis,” American Journal of Human Genetics, vol. 59, p. 676, 1996.View at: Google Scholar
S. Georgopoulos, D. Plows, and G. Kollias, “Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice,” Journal of Inflammation, vol. 46, no. 2, pp. 86–97, 1996.View at: Google Scholar
J. Trifunovic Cvetkovic, S. Wållberg-Jonsson, B. Stegmayr, S. Rantapää-Dahlqvist, and A. K. Lefvert, “Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes,” The Journal of Rheumatology, vol. 29, no. 2, pp. 212–219, 2002.View at: Google Scholar
S. L. Ferrari, L. Ahn-Luong, P. Garnero, S. E. Humphries, and S. L. Greenspan, “Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 1, pp. 255–259, 2003.View at: Publisher Site | Google Scholar
P. Jerrard-Dunne, M. Sitzer, P. Risley et al., “Interleukin-6 promoter polymorphism modulates the effects of heavy alcohol consumption on early carotid artery atherosclerosis: the carotid atherosclerosis progression study (CAPS),” Stroke, vol. 34, no. 2, pp. 402–407, 2003.View at: Publisher Site | Google Scholar
D. Bikle, “Nonclassic actions of vitamin D,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, pp. 26–34, 2009.View at: Google Scholar
A. Hossein-nezhad and M. F. Holick, “Optimize dietary intake of vitamin D: an epigenetic perspective,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 15, pp. 567–579, 2012.View at: Google Scholar
A. Hossein-nezhad and M. F. Holick, “Vitamin D for health: a global perspective,” Mayo Clinic Proceedings, vol. 88, pp. 720–755, 2013.View at: Google Scholar
X. Jiang, D. P. Kiel, and P. Kraft, “The genetics of vitamin D,” Bone, 2018.View at: Google Scholar
Y. M. Hussien, A. Shehata, R. A. Karam, S. S. Alzahrani, H. Magdy, and A. M. El-Shafey, “Polymorphism in vitamin D receptor and osteoprotegerin genes in Egyptian rheumatoid arthritis patients with and without osteoporosis,” Molecular Biology Reports, vol. 40, no. 5, pp. 3675–3680, 2013.View at: Publisher Site | Google Scholar
K. Tizaoui, W. Kaabachi, M. Ouled Salah, A. Ben Amor, A. Hamzaoui, and K. Hamzaoui, “Vitamin D receptor TaqI and ApaI polymorphisms: a comparative study in patients with Behçet's disease and Rheumatoid arthritis in Tunisian population,” Cellular Immunology, vol. 290, no. 1, pp. 66–71, 2014.View at: Publisher Site | Google Scholar
A. K. Bhalla, E. P. Amento, T. L. Clemens, M. F. Holick, and S. M. Krane, “Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation,” The Journal of Clinical Endocrinology & Metabolism, vol. 57, no. 6, pp. 1308–1310, 1983.View at: Publisher Site | Google Scholar
M. T. Cantorna and B. D. Mahon, “Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence,” Experimental Biology and Medicine (Maywood), vol. 229, pp. 1136–1142, 2004.View at: Google Scholar
L. L. Ritterhouse, S. R. Crowe, T. B. Niewold et al., “Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus,” Annals of Rheumatic Diseases, vol. 70, pp. 1569–1574, 2011.View at: Google Scholar
J. I. Szekely and A. Pataki, “Effects of vitamin D on immune disorders with special regard to asthma, COPD and autoimmune diseases: a short review,” Expert Review of Respiratory Medicine, vol. 6, pp. 683–704, 2012.View at: Google Scholar
J. Luo, H. Wen, H. Guo, Q. Cai, S. Li, and X. Li, “1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis,” BioMed Research International, vol. 2013, Article ID 101805, 9 pages, 2013.View at: Publisher Site | Google Scholar
B. Villaggio, S. Soldano, and M. Cutolo, “1,25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages,” Clinical and Experimental Rheumatology, vol. 30, pp. 934–938, 2012.View at: Google Scholar
B. J. Jones and P. J. Twomey, “Issues with vitamin D in routine clinical practice,” Rheumatology, vol. 47, pp. 1267-1268, 2008.View at: Google Scholar
M. T. Cantorna and B. D. Mahon, “D-hormone and the immune system,” The Journal of Rheumatology, vol. 76, pp. 11–20, 2005.View at: Google Scholar
M. T. Cantorna, Y. Zhu, M. Froicu, and A. Wittke, “Vitamin D status, 1, 25-dihydroxyvitamin D3, and the immune system,” The American Journal of Clinical Nutrition, vol. 80, pp. 1717s–1720s, 2004.View at: Google Scholar
A. F. Edrees, S. N. Misra, and N. I. Abdou, “Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions,” Clinical and Experimental Rheumatology, vol. 23, no. 4, pp. 469–474, 2005.View at: Google Scholar
X. Gu, B. Gu, X. Lv et al., “1, 25-dihydroxy-vitamin D3 with tumor necrosis factor-alpha protects against rheumatoid arthritis by promoting p53 acetylation-mediated apoptosis via Sirt1 in synoviocytes,” Cell Death & Disease, vol. 7, no. 10, Article ID e2423, 2016.View at: Publisher Site | Google Scholar
A. E. Koch, S. L. Kunkel, and R. M. Strieter, “Cytokines in rheumatoid arthritis,” Journal of Investigative Medicine, vol. 43, no. 1, pp. 28–38, 1995.View at: Google Scholar
E. R. Pettipher, G. A. Higgs, and B. Henderson, “Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 83, no. 22, pp. 8749–8753, 1986.View at: Publisher Site | Google Scholar
B. Villaggio, S. Soldano, and M. Cutolo, “1,25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages,” Clinical and Experimental Rheumatology, vol. 30, no. 6, pp. 934–938, 2012.View at: Google Scholar
J. Kong, S. A. Grando, and Y. C. Li, “Regulation of IL-1 family cytokines IL-1α, IL-1 receptor antagonist, and IL-18 by 1,25-Dihydroxyvitamin D3 in primary keratinocytes,” The Journal of Immunology, vol. 176, p. 3780, 2006.View at: Google Scholar
D. Eklund, H. L. Persson, M. Larsson et al., “Vitamin D enhances IL-1beta secretion and restricts growth of mycobacterium tuberculosis in macrophages from TB patients,” International Journal of Mycobacteriology, vol. 2, pp. 18–25, 2013.View at: Google Scholar
P. E. Lipsky, “Interleukin-6 and rheumatic diseases,” Arthritis Research and Therapy, vol. 8, p. S4, 2006.View at: Google Scholar
T. Kishimoto, S. Akira, M. Narazaki, and T. Taga, “Interleukin-6 family of cytokines and gp130,” Blood, vol. 86, no. 4, pp. 1243–1254, 1995.View at: Google Scholar
A. Desgeorges et al., “Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid,” The Journal of Rheumatology, vol. 24, pp. 1510–1516, 1997.View at: Google Scholar
F. A. Houssiau, J.-P. Devogelaer, J. van Damme, C. N. de Deuxchaisnes, and J. van Snick, “Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides,” Arthritis & Rheumatism, vol. 31, no. 6, pp. 784–788, 1988.View at: Publisher Site | Google Scholar
L. Nonn, L. Peng, D. Feldman, and D. M. Peehl, “Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D,” Cancer Research, vol. 66, no. 8, pp. 4516–4524, 2006.View at: Publisher Site | Google Scholar
M.-L. Xue, H. Zhu, A. Thakur, and M. Willcox, “1α,25-Dihydroxyvitamin D3 inhibits pro-inflammatory cytokine and chemokine expression in human corneal epithelial cells colonized with Pseudomonas aeruginosa,” Immunology & Cell Biology, vol. 80, no. 4, pp. 340–345, 2002.View at: Publisher Site | Google Scholar
J. A. Huhtakangas, J. Veijola, S. Turunen et al., “1,25(OH)2D3 and calcipotriol, its hypocalcemic analog, exert a long-lasting anti-inflammatory and anti-proliferative effect in synoviocytes cultured from patients with rheumatoid arthritis and osteoarthritis,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 173, pp. 13–22, 2017.View at: Publisher Site | Google Scholar
J. P. van Hamburg, P. S. Asmawidjaja, N. Davelaar et al., “Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin‐17A production,” Arthritis & Rheumatism, vol. 63, pp. 73–83, 2010.View at: Google Scholar
C. Daniel, N. A. Sartory, N. Zahn, H. H. Radeke, and J. M. Stein, “Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile,” The Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 1, pp. 23–33, 2008.View at: Publisher Site | Google Scholar
J. R. Mora, M. Iwata, and U. H. Von Andrian, “Vitamin effects on the immune system: vitamins A and D take centre stage,” Nature Reviews Immunology, vol. 8, pp. 685–698, 2008.View at: Google Scholar
S. H. Chang, Y. Chung, and C. Dong, “Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression,” Journal of Biological Chemistry, vol. 285, pp. 38751–38755, 2010.View at: Google Scholar
E. M. Colin, P. S. Asmawidjaja, J. P. van Hamburg et al., “1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis,” Arthritis & Rheumatology, vol. 62, no. 1, pp. 132–142, 2010.View at: Publisher Site | Google Scholar
G. S. Buchan, K. Barrett, T. Fujita, T. Taniguchi, R. Maini, and M. Feldmann, “Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma,” Clinical and Experimental Immunology, vol. 71, pp. 295–301, 1988.View at: Google Scholar
A. Takeuchi, G. S. Reddy, T. Kobayashi, T. Okano, J. Park, and S. Sharma, “Nuclear factor of activated T cells (NFAT) as a molecular target for 1a, 25-dihydroxyvitamin D3-mediated effects,” Journal of Immunology, vol. 160, pp. 209–218, 1998.View at: Google Scholar
I. Alroy, T. L. Towers, and L. P. Freedman, “Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor,” Molecular and Cellular Biology, vol. 15, no. 10, pp. 5789–5799, 1995.View at: Publisher Site | Google Scholar
A. Boonstra, F. J. Barrat, C. Crain, V. L. Heath, H. F. J. Savelkoul, and A. O'Garra, “1α,25-Dihydroxyvitamin D3 has a direct effect on naive CD4+ T cells to enhance the development of Th2 cells,” The Journal of Immunology, vol. 167, no. 9, pp. 4974–4980, 2001.View at: Publisher Site | Google Scholar
L. Petrovic-Rackov and N. Pejnovic, “Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis,” Clinical Rheumatology, vol. 25, pp. 448–452, 2006.View at: Google Scholar
X. Rausch-Fan, F. Leutmezer, M. Willheim et al., “Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific Th cell clones by 1α,25-dihydroxyvitamin D3,” International Archives of Allergy and Immunology, vol. 128, no. 1, pp. 33–41, 2002.View at: Publisher Site | Google Scholar
D. D'Ambrosio, M. Cippitelli, M. G. Cocciolo et al., “Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-κB downregulation in transcriptional repression of the p40 gene,” The Journal of Clinical Investigation, vol. 101, no. 1, pp. 252–262, 1998.View at: Publisher Site | Google Scholar
G. Penna and L. Adorini, “1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation,” The Journal of Immunology, vol. 164, pp. 2405–2411, 2000.View at: Google Scholar
L. E. Jeffery, K. Raza, and M. Hewison, “Vitamin D in rheumatoid arthritistowards clinical application,” Nature Reviews Rheumatology, vol. 12, p. 201, 2015.View at: Google Scholar
L. A. Merlino, J. Curtis, T. R. Mikuls, J. R. Cerhan, L. A. Criswell, and K. G. Saag, “Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa women's health study,” Arthritis & Rheumatism, vol. 50, pp. 72–77, 2004.View at: Google Scholar
X. Feng, C. Lv, F. Wang, K. Gan, M. Zhang, and W. Tan, “Modulatory effect of 1,25-dihydroxyvitamin D3 on IL1β-induced RANKL, OPG, TNFα, and IL-6 expression in human rheumatoid synoviocyte MH7A,” Clinical and Developmental Immunology, vol. 2013, Article ID 160123, 8 pages, 2013.View at: Publisher Site | Google Scholar
G. G. Song, S.-C. Bae, and Y. H. Lee, “Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis,” Clinical Rheumatology, vol. 31, pp. 1733–1739, 2012.View at: Google Scholar
A. Raczkiewicz, B. Kisiel, M. Kulig, and W. Tlustochowicz, “Vitamin D status and its association with quality of life, physical activity, and disease activity in rheumatoid arthritis patients,” Journal of Clinical Rheumatology, vol. 21, 2015.View at: Google Scholar
Y. H. Lee and S. C. Bae, “Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis,” Clinical and Experimental Rheumatology, vol. 34, pp. 827–833, 2016.View at: Google Scholar
M. Cutolo, K. Otsa, K. Laas et al., “Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe,” Clinical and Experimental Rheumatology, vol. 24, pp. 702–704, 2006.View at: Google Scholar
R. Sharma, R. Saigal, L. K. Goyal et al., “Estimation of vitamin D levels in rheumatoid arthritis patients and its correlation with the disease activity,” The journal of the association of Physicians of India, vol. 62, pp. 678–681, 2014.View at: Google Scholar
T. A. Gheita, S. Sayed, H. A. Gheita, and S. A. Kenawy, “Vitamin D status in rheumatoid arthritis patients: relation to clinical manifestations, disease activity, quality of life and fibromyalgia syndrome,” International Journal of Rheumatic Diseases, vol. 19, pp. 294–299, 2014.View at: Publisher Site | Google Scholar
M. A. Atwa, M. G. Balata, A. M. Hussein, N. I. Abdelrahman, and H. H. Elminshawy, “Serum 25-hydroxyvitamin D concentration in patients with psoriasis and rheumatoid arthritis and its association with disease activity and serum tumor necrosis factor-alpha,” Saudi Medical Journal, vol. 34, no. 8, pp. 806–813, 2013.View at: Google Scholar
J. Lin, J. Liu, M. L. Davies, and W. Chen, “Vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis,” PLoS One, vol. 11, Article ID e0146351, 2016.View at: Google Scholar
J. Vojinovic, A. Tincani, A. Sulli et al., “European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new patient reported outcome questionnaire (D-PRO),” Autoimmunity Reviews, vol. 16, no. 5, pp. 548–554, 2017.View at: Publisher Site | Google Scholar
S. Cecchetti, Z. Tatar, P. Galan et al., “Prevalence of vitamin D deficiency in rheumatoid arthritis and association with disease activity and cardiovascular risk factors: data from the COMEDRA study,” Clinical and Experimental Rheumatology, vol. 34, pp. 984–990, 2016.View at: Google Scholar
T. Baykal, K. Senel, F. Alp, A. Erdal, and M. Ugur, “Is there an association between serum 25-hydroxyvitamin D concentrations and disease activity in rheumatoid arthritis?” Bratislava Medical Journal, vol. 113, pp. 610-611, 2012.View at: Google Scholar
M. Sahebari, Z. Mirfeizi, Z. Rezaieyazdi, H. Rafatpanah, and L. Goshyeshi, “25(OH) vitamin D serum values and rheumatoid arthritis disease activity (DA S28 ESR),” Caspian Journal of Internal Medicine, vol. 5, pp. 148–155, 2014.View at: Google Scholar
M. Varenna, M. Manara, F. P. Cantatore et al., “Determinants and effects of vitamin D supplementation on serum 25-hydroxy-vitamin D levels in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 30, pp. 714–719, 2012.View at: Google Scholar
N. Hajjaj-Hassouni, N. Mawani, F. Allali et al., “Evaluation of vitamin D status in rheumatoid arthritis and its association with disease activity across 15 countries: 'the comora study',” International Journal of Rheumatology, vol. 2017, Article ID 5491676, 8 pages, 2017.View at: Publisher Site | Google Scholar
Y. Nakamura, T. Suzuki, T. Yoshida, H. Yamazaki, and H. Kato, “Vitamin d and calcium are required during denosumab treatment in osteoporosis with rheumatoid arthritis,” Nutrients, vol. 9, no. 5, 2017.View at: Google Scholar
Y. Liu and H. Wen, “Impact of vitamin deficiency on clinical parameters in treatment-na∩ve rheumatoid arthritis patients,” Zeitschrift für Rheumatologie, vol. 77, pp. 833–840, 2018.View at: Google Scholar
N. Maruotti and F. P. Cantatore, “Vitamin D and the immune system,” The Journal of Rheumatology, vol. 37, p. 491, 2010.View at: Google Scholar
H. Yesil, U. Sungur, S. Akdeniz, G. Gurer, B. Yalcin, and U. Dundar, “Association between serum vitamin D levels and neuropathic pain in rheumatoid arthritis patients: a cross-sectional study,” International Journal of Rheumatic Diseases, vol. 21, no. 2, pp. 431–439, 2018.View at: Publisher Site | Google Scholar
S. Mateen, S. Moin, S. Shahzad, and A. Q. Khan, “Level of inflammatory cytokines in rheumatoid arthritis patients: Correlation with 25-hydroxy vitamin D and reactive oxygen species,” Plos One, vol. 12, Article ID e0178879, 2017.View at: Google Scholar
L.-M. Tan, T.-T. Long, X.-L. Guan et al., “Diagnostic value of vitamin D status and bone turnover markers in rheumatoid arthritis complicated by osteoporosis,” Annals of Clinical and Laboratory Science, vol. 48, pp. 197–204, 2018.View at: Google Scholar